Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11389510 Controlled-release CNP agonists with low initial NPR-B activity

Patent 11389510 was granted and assigned to Ascendis Pharma on July, 2022 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity

The present invention relates to a controlled-release CNP agonist from which CNP agonist is released with a release half-life of at least 6 hours under physiological conditions and which controlled-release CNP agonist has an EC

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11389510 Controlled-release CNP agonists with low initial NPR-B activity

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.